Anzeige
Mehr »
Donnerstag, 12.02.2026 - Börsentäglich über 12.000 News
Top-Ergebnisse: 1,75 g/t Gold über 30,4 Meter + massives Tagebau-Potenzial
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
GlobeNewswire (Europe)
289 Leser
Artikel bewerten:
(1)

Cytel Partners with Nested Knowledge to Power the Next Generation of AI-Enhanced LiveSLR for HEOR and HTA

Cambridge, MA and St. Paul, MN, May 09, 2025, a global leader in evidence generation and data-driven decision-making, today announced a partnership with Nested Knowledge, a pioneer in AI-powered systematic literature review technology. The partnership pairs Cytel's proprietary LiveSLR® software with Nested Knowledge's advanced AI platform, creating an advanced, fully auditable living evidence platform available for Health Economics and Outcomes Research (HEOR) and Health Technology Assessment (HTA).

This collaboration enables Cytel's unique LiveSLR® platform to be powered by Nested Knowledge - an offering that combines Cytel's industry-leading SLR methodology and domain expertise with cutting-edge AI-driven automation. Unique in the field of evidence evaluation and synthesis, Cytel will deliver a distinct advantage through its expert-led approach to search strategy design, expansive database access, and superior evidence reporting capabilities.

"Cytel is excited to work with Nested Knowledge to ensure our clients can realize the advantages of our LiveSLR® and Nested Knowledge best-in-class offerings for their evidence and health economics needs" noted Wyatt Gotbetter, Global Head of Cytel Evidence, Value and Access. "With LiveSLR® and Nested Knowledge software, our customers can feel confident we're employing the standard and get access to a set of differentiated deliverables to interact with their HEOR living evidence."

As the SLR market grows more competitive - Cytel stands apart by offering:

  • Best-in-class AI-enabled screening and extraction
  • Automated generation of unlimited reports filtered by PICO criteria, ideal for global-to-local adaptation
  • Superior search strategies based on broad database access and deep domain knowledge
  • Industry-leading analytic and reporting capabilities, tailored to HTA and reimbursement decision-makers

Keith Kallmes, President of Nested Knowledge, emphasized the strength of the collaboration: "With their unique LiveSLR content offering, technically expert researchers, and nimble delivery model, Cytel's team integrates perfectly with health economists' complex workflows, allowing them to meet the changing demands for HTA-grade evidence in an evolving global pharmaceutical marketplace. We're honored to be working with them and look forward to supporting our mutual clients."

With growing demand for real-time, rigorous, and transparent evidence, the pairing of Cytel's LiveSLR® platform with Nested Knowledge's software positions Cytel at the forefront of an evolving global landscape - offering life sciences innovators an unmatched, AI-enabled solution for strategic decision-making.

About Cytel
Cytel a world leading data-science CRO, driving advancements in human health through robust analytics and innovative clinical trial software. For nearly four decades, we have set the standard in adaptive trial design, leveraging extensive data insights to inform strategy throughout every phase of drug development and commercialization. Our mission is clear: accelerate drug development, enhance success rates, and deliver better patient outcomes. With a comprehensive suite of services from innovative trial design to end-to-end biometrics and real-world evidence, our specialized, multidisciplinary team ensures optimal strategies for pre-clinical research, trial execution, market access, and reimbursement.

About Nested Knowledge
Nested Knowledge is a software company transforming how evidence synthesis is performed and consumed. Their AI-powered platform supports end-to-end workflows for systematic literature reviews, from search to visualization, and offers "living" evidence libraries that update as new data emerges.

LiveSLR® is a registered trademark of Cytel Inc. All rights reserved.



Sofie Vandevyver Cytel sofie.vandevyver@cytel.com

© 2025 GlobeNewswire (Europe)
Favoritenwechsel - diese 5 Werte sollten Anleger im Depot haben!
Das Börsenjahr 2026 ist für viele Anleger ernüchternd gestartet. Tech-Werte straucheln, der Nasdaq 100 tritt auf der Stelle und ausgerechnet alte Favoriten wie Microsoft und SAP rutschen zweistellig ab. KI ist plötzlich kein Rückenwind mehr, sondern ein Belastungsfaktor, weil Investoren beginnen, die finanzielle Nachhaltigkeit zu hinterfragen.

Gleichzeitig vollzieht sich an der Wall Street ein lautloser Favoritenwechsel. Während viele auf Wachstum setzen, feiern Value-Titel mit verlässlichen Cashflows ihr Comeback: Telekommunikation, Industrie, Energie, Pharma – die „Cashmaschinen“ der Realwirtschaft verdrängen hoch bewertete Hoffnungsträger.

In unserem aktuellen Spezialreport stellen wir fünf Aktien vor, die genau in dieses neue Marktbild passen: solide, günstig bewertet und mit attraktiver Dividende. Werte, die nicht nur laufende Erträge liefern, sondern auch bei Marktkorrekturen Sicherheit bieten.

Jetzt den kostenlosen Report sichern – bevor der Value-Zug 2026 endgültig abfährt!

Dieses exklusive PDF ist nur für kurze Zeit gratis verfügbar.
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.